Novel Microplate Design Improves Assay Performance
Porvair Sciences has developed the Krystal 2000 microplate range to address performance limiting well-to-well crosstalk inherent in most assay plates.
Incorporating unique individual clear cups molded into either a black or white polypropylene matrix, crosstalk is eliminated and the sensitivity, photometric accuracy and repeatability of your bottom reading absorbance, fluorescence and luminescence measurements markedly improved.
Maintaining industry standard 96-well microplate dimensions the Krystal 2000 range is fully compatible with all commercially available plate readers, robotic sample processors and automated liquid handling systems.
Constructed in ultra-pure grade polystyrene, Krystal 2000 microplates are available in opaque white, solid black and black and white combination formats. For sensitive fluorescence measurements the black plate provides the all-absorbing background needed to minimise background interference. The opaque white plate maximizes reflectivity enabling even weakly emitting luminescence assays to be routinely undertaken.
In addition to optimized luminescence and fluorescence measurements the unique design offers improved cell binding efficiency and allows the convenience of direct measurements on bottom reading spectrophotometers and inverted microscopes.
To download a technical report that evaluates well-to-well crosstalk in commercially available microplates used for luminescence measurements please visit www.porvair-sciences.com/
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...